16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...

Professors Ugur Sahin and Ozlem Tureci co-founded the German company BioNTech in 2008, exploring new technology involving messenger RNA (mRNA), to treat cancer. When the pandemic struck they ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...

German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327 ...

(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net profit of 198.1 million euros or 0.81 euros per share for the third quarter ...

Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...